Loading...

LXEO LEXEO THERAPEUTICS INC Management Changes 8-K Filing

LX T

LX

LEXEO THERAPEUTICS INC

(LXEO)

2025 8-K

Financial Results Update

Director Appointment

Business Highlights

Management Change

Management Changes

Positive Clinical Data

Financial Results Announced

Funding Announcements

Regulatory Update

CFO Transition Announcement

Equity Offerings

Financial Statements

Clinical Data Announcement

Financial Results

Corporate Presentation

CFO Appointment

Management Change

Clinical Data Release

Corporate Update

External Links:

On August 14, 2025, Lexeo Therapeutics, Inc. announced the appointment of Louis Tamayo as Chief Financial Officer, effective August 15, 2025, succeeding Dr. Kyle Rasbach who resigned on the same date. Tamayo’s initial salary is $480,000 with stock options and bonuses based on performance.

AI Assistant

LEXEO THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.